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Background: Toll-like receptor (TLR) agonists have important properties that can be exploited for immunotherapy
against tumors. Locally injected immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG-ODNs),
which are TLR9 agonists, have shown promise in cancer models. Several studies have demonstrated that these
motifs have immunologic effects similar to those of bacterial DNA and can stimulate monocytes, macrophages,
dendritic, and B cells, which then produce several proinflammatory cytokines. However, these CpG-ODNs appear to
produce opposite effects on tumor B cells.
Methods: In this study, we investigated the direct effects of a murine class B CpG (1826) ODNs on lymphoma
B cells in vitro and in vivo, using mouse models of non-Hodgkin B lymphomas developing in immunoprivileged
sites, specifically the brain and the eye, and in subcutaneous sites.
Results: In vitro, CpG-ODNs produced antiproliferative and proapoptotic effects on lymphoma B cells. In vivo, it had
an antitumor effect when injected into tumors in murine models of subcutaneous lymphoma (SCL) and primary
cerebral lymphoma (PCL). However, its intravitreal administration into a primary intraocular lymphoma (PIOL) mouse
model did not produce an antitumor effect. In vitro experiments using supernatant from mouse PIOL samples
demonstrated that the PIOL molecular microenvironment inhibits the antiproliferative effect of CpG-ODNs on
lymphoma B-cells.
Conclusions: Responsiveness to CpG stimulation differs in subcutaneous, cerebral, and ocular tumors, according to
the tumoral and molecular microenvironment, and this should be considered for further therapeutic approaches.
Keywords: TLR, CpG-DNA, Non-Hodgkin B-cell lymphoma, Subcutaneous lymphoma, Primary cerebral lymphoma,
Primary intraocular lymphoma, Tumor microenvironmentBackground
Toll-like receptors (TLRs) are pattern recognition receptors
that trigger innate and adaptive immune responses. Trig-
gering TLRs activates a set of common proinflammatory
genes and leads to the expression of antimicrobial effector
cells and to production of inflammatory cytokines [1].
Agonists for TLRs have been identified and are being
developed as new drugs and vaccine adjuvants to treat can-
cer, allergies, and infectious diseases [2]. In particular,
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distribution, and reproduction in any mediumwhich are TLR9 agonists, have shown promise against
several types of tumors, including renal cell carcinoma,
glioblastoma, melanoma, cutaneous T-cell lymphoma, and
non-Hodgkin lymphoma [3]. Unmethylated CpG-DNA
motifs have immunologic effects similar to those of bacter-
ial DNA and can stimulate monocytes, macrophages, and
dendritic and B cells; these then produce several Th1-type
cytokines [4].
At least 3 structurally distinct classes of synthetic CpG-
ODNs have been described, all capable of stimulating cells
that express TLR9 [5,6]. CpG-B (also known as class-B
CpG or K-type CpG) ODNs encode multiple CpG motifs
on a phosphorothioate backbone and trigger the differen-
tiation of antigen-presenting cells and the proliferationd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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an established immunostimulatory agent, its direct effect
on normal and tumor B cells seems to differ: CpG-ODNs
stimulate proliferation of healthy B cells, activate their
production of polyreactive immunoglobulins, and protect
them from apoptosis [6-8]. On the other hand, these
ODNs predominantly activate malignant B cells and then
increase the rate of cell death, thus reducing survival of
malignant B cells over time [9-11].
Different types of non-Hodgkin B-cell lymphomas differ
in their responsiveness to CpG-DNA, and only limited in-
formation is available [9] about the sensitivity of malignant
B cells to this DNA motif according to their in vivo micro-
environment, particularly in immune sanctuaries such as
the brain and eyes. Unlike systemic lymphoma, primary
cerebral lymphoma (PCL) and primary intraocular lymph-
oma (PIOL) are subsets of primary central nervous system
lymphoma (PCNSL), and they affect immunologically
privileged organs. Both usually appear as a diffuse large
B-cell non-Hodgkin lymphoma in which malignant
lymphoid cell types not normally present in the brain or
eye are detected [12]. The internal tissues of the brain and
eye are usually protected from the inflammatory processes
mediated by the immune system.
In this study, we compare the effect of CpG-ODNs on
cerebral and ocular diffuse large B-cell lymphoma and on
subcutaneous lymphomas (SCL). We show that A20.IIA
murine B-cell lymphoma expressed high levels of en-
dogenous TLR9 protein that produced an antiproliferative
effect when stimulated in vitro by CpG-ODNs. A
proapoptotic effect accompanied this reduced prolifera-
tion. In vivo local administration had a similar antitumor
effect on subcutaneous and cerebral lymphomas. How-
ever, local administration of CpG-ODNs in a PIOL mouse
model did not produce an antitumor effect. In vitro exper-
iments with supernatant from ocular lymphoma samples
demonstrated that the molecular microenvironment of
PIOL counteracts the direct antiproliferative effect of
CpG-ODNs on lymphoma B-cells. These findings show
that cerebral and ocular tumor cells differ in their respon-
siveness to CpG stimulation according to the tumor envir-
onment. The microenvironment of the eye must be
further characterized to identify the negative regulators.Methods
Reagents
Nuclease-stable phosphorothioate-modified CpG 1826
(CpG) with 5_-TCCATGACGTTCCTGACGTT (the nu-
cleotides in bold represent the immunostimulatory CpG
sequences), fluorescein isothiocyanate (FITC)-conjugated
CpG 1826 ODNs, and control 1826 ODN with 5_-TCC
ATGAGCTTCCTGAGCTT were purchased from InvivoGen
(Cayla, France).Cells
A20.IIA is an FcγR-negative clone originating from the
A20-2 J B-cell lymphoma line [13]. For in vivo experi-
ments, A20.IIA cells were transfected by an electropor-
ation system with the green fluorescent protein (GFP)
gene. These cells, hereafter referred to as A20.IIA or A20.
IIA-GFP cells as appropriate, were maintained at 37°C, 5%
CO2 in complete Roswell Park Memorial Institute (RPMI)
1640 Medium Glutamax plus (RPMI; Gibco-Invitrogen,
France) supplemented with 10% fetal calf serum (FCS;
PAA Laboratories, Germany), 100 μg/mL penicillin and
100 μg/mL streptomycin (both from Eurobio, France),
10 mM sodium pyruvate (Gibco-Invitrogen), and 50 μM
2-mercaptoethanol (Gibco-Invitrogen). The A20.IIA-GFP
cell culture was also supplemented with 0.5 mg/mL
neomycin (G418; Gibco-Invitrogen). To obtain the A20.
IIA-luc2 cell line, A20.IIA cells were transfected with
pGL4.50[luc2/CMV/hygro] (Promega), in the AMAXA
Nucleofector II device (Lonza, Switzerland) and were cul-
tured in 0.75 mg/mL hygromycin B (Gibco-Invitrogen)
medium.
Proliferation assay
A20.IIA cells at a concentration of 105cells/mL were in-
cubated with serial dilutions of CpG 1826 or control
1826 ODNs at concentrations ranging from 0.0003 to
60 μg/mL or with complete RPMI medium alone. After
3 days, [3H] thymidine (GE Healthcare) was added for
the last 4 h. Cells were harvested onto fiber filters and
[3H] thymidine incorporation was measured in a scintil-
lation counter (Microbeta, Perkin Elmer).
Apoptosis assay
A20.IIA cells (104) were cultured in complete RPMI
medium in 96-well plates in the presence or absence of
3 μg/mL or 30 μg/mL of CpG or control ODNs. Staining
with Annexin V/allophycocyanin (APC) and propidium
iodide (PI) (BD Biosciences, France) was performed 72 h
later and then analyzed by flow cytometry. Apoptotic cells
were defined as those positive for Annexin V and PI.
Mice
Female BALB/c mice (H-2d) were obtained from Charles
River Laboratories (L’Arbresle, France) and used between
6 and 8 weeks of age. They were provided with sterile
food and water ad libitum and kept on a 12-hour light–
dark cycle. All procedures involving mice conformed
with European Union guidelines, French regulations for
animal experimentation (Ministry of Agriculture Act No.
2001–464, May 2001), and the guidelines of the Institut
National de la Santé et de la Recherche Médicale Commit-
tee on Animal Research, and were approved by the rele-
vant local committees (Charles Darwin Ethics Committee
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Tumor implantation
Mice were first anesthetized by intraperitoneal injection
of a mixture containing 120 mg/kg of ketamine (Virbac,
France) and 6 mg/kg of xylazine (Rompun 2%; Bayer
Healthcare). To obtain a subcutaneous lymphoma (SCL)
murine model, BALB/c mice were inoculated subcutane-
ously with 5 × 106 A20.IIA-GFP tumor cells in a final
volume of 50 μL of RPMI, at 2 different sites: the right
and left abdomen. For the intracerebral tumor implant-
ation, anesthetized mice were immobilized on a stereo-
taxic frame (David Kopf Instruments, Tujunga, CA,
USA). Tumor cells (5 × 104 in a final volume of 2 μL
RPMI) were injected into the specific cerebral location
(right striatum), located 2 mm to the right of the medial
suture and 0.4 mm in front of the bregma, through a
Hamilton syringe attached to a penetrating depth con-
troller. The penetrating depth of the syringe was 2.5 mm
from the surface of the brain. Each injection delivered
the solution slowly, and the syringe was held in place for
an additional minute to reduce backfilling of tumor cells.
For the intravitreal tumor implantation, we used a 32-
gauge needle attached to a syringe to inject 104 cells in a
final volume of 2 μL of RPMI into the vitreous under a
dissecting microscope. Lacrinorm 2% (Bauch&Lomb)
drops were instilled after intravitreal injection. For each
tumor model, control mice received either 1× phosphate-
buffered saline (pH7.4; PBS) or control 1826 ODNs
instead of CpG 1826 ODNs.
Treatment injections
Tumor growth in the SCL model was monitored by cali-
per measurements 3 times a week. Treatment began
when the longest tumor diameter reached 0.5 to 0.7 cm.
The mice then received daily intratumor injections of
CpG-ODNs for 5 days (100 μg per injection in a final
volume of 50 μL RPMI) in the right tumor only; the left
tumor served as an untreated control tumor. Mice were
killed one week after the last treatment injection.
Lymphomas established in the brain and eye were
treated 7 days after tumor inoculation, by a single local in-
jection of 60 μg (brain) or 20 μg (eye) CpG-ODNs in 2 μL
of RPMI (treatment groups) or 2 μL of PBS (control
groups). Tumor burden was analyzed in the sacrificed
mice one week after treatment administration.
Isolation of brain, ocular and subcutaneous lymphomas
The tumor-injected brains and eyes and the subcutane-
ous tumors were harvested one week after treatment in-
jection, minced with surgical scissors, incubated for
30 minutes in RPMI containing 0.1 mg/mL DNAse I
(Roche Diagnostics, Meylan, France) and 1.67 WünchU/mL Liberase (Roche), and filtered through a 70-μm
membrane (BD Falcon). Mononuclear cells were sepa-
rated from myelin with a Percoll cell density gradient.In vivo tumor growth assay
The A20.IIA (1 × 104) cells expressing luciferase (luc2 gene)
were injected via subcutaneous, intracerebral or intravitreal
routes into immunocompetent 7-week-old BALB/c mice.
CpG or control ODNs were administered in situ for each
lymphoma model according to the same experimental de-
sign and at the time points and doses described above. The
tumor burden was thereafter monitored by biolumines-
cence imaging. Mice were injected intraperitoneally with
150 mg/kg of D-luciferin potassium salt (Interchim) and
underwent imaging within the next 10 minutes with the
IVIS LUMINA II (Caliper LS) imaging system. The ex-
posure time was set to optimize the signal and obtain
the best signal-to-noise ratio. The bioluminescence sig-
nal is expressed in photons per second.Supernatant harvesting
Mice were implanted with tumor cells in the brain (PCL),
eye (PIOL) or flank (SCL) or injected with PBS in the eye
(PIE). Either 14 days later (brain and eye) or when tumor
diameter reached 0.5 to 0.7 cm (SCL), the relevant cells
were isolated and cultured for 36 h in complete RPMI
medium in 96-well (104 cells per well) plates. Supernatant
was then harvested from each well.Flow cytometry
To analyze TLR9 expression on A20.IIA cells, these
cells underwent intracellular staining with the Fixation/
Permeabilization solution kit (BD Biosciences) and an
anti-TLR9/PE mAb (BD Biosciences).
Tumor burden was analyzed according to the following
protocol: Fc receptors were saturated for 20 min with
10 μg/mL of anti-CD16/CD32 mAb (clone 2.4.G2), and
then the cells were incubated for 20 min with either rat
IgG2a anti-CD19/APC mAb, or the corresponding isotypic
mAb control (all from BD Biosciences). The living cells
were defined with side scatter (SSC) and forward scatter
(FSC) after autofluorescent cells were excluded. Cell phe-
notypes were analyzed with the LSRII cytometer and Diva
software (BD Biosciences).Statistical analysis
Comparisons used Student’s t-test, performed with
GraphPad Prism (GraphPad Software, La Jolla, CA,
USA). Statistical significance was defined by p values less
than 0.05.
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CpG-ODNs inhibit cell proliferation and induce apoptosis
of malignant A20.IIA B cells in vitro
TLR9 is an intracellular receptor that recognizes CpG-
DNA. Cell stimulation by CpG motifs requires that they
bind to TLR9. We therefore began by confirming with
flow cytometry that A20.IIA B lymphoma cells express
TLR9 (Figure 1A).
We next evaluated the direct effect of CpG-ODNs on
the proliferation of A20.IIA lymphoma in vitro. Based on
our study of its proliferation kinetics (data not shown),
tumor cells were incubated for 72 h with CpG 1826 ODNs
at concentrations ranging from 0.0003 to 30 μg/mL. Cell
proliferation was measured with the [3H] thymidine in-
corporation assay. The CpG-ODNs inhibited A20.IIA [3H]
thymidine incorporation in a dose-dependent manner,
whereas control ODNs had no effect on cell proliferation
(Figure 1B). The maximum inhibitory effect was obtained
from 0.3 to 30 μg/mL of CpG-ODNs.
Based on these results, we analyzed the induction of
apoptosis of A20.IIA cells by CpG- ODNs and found
that they induced apoptosis of about 30 to 35% of the
cells (that is, 30-35% stained positive for Annexin V and
PI), compared with 5% for RMPI Medium and 5-10%





































Figure 1 CpG inhibits cell proliferation and induces apoptotic death o
TLR9 expression by A20.IIA cells after anti-TLR9 Ab staining (filled histogram
proliferation of A20.IIA cells in vitro. 104 A20.IIA cells were stimulated for 72
from 0.0003 to 30μg/mL or with medium alone. The incorporation of the [
**P < 0.01. The data shown are representative of 1 of 3 experiments. (C) Cp
for 72 hours with CpG or control ODNs at 3 and 30 μg/mL, or medium alo
cytometric analysis. ***P < 0.001.Lymphoma cell responsiveness to CpG sequences differs
according to their tissue microenvironment
After showing that the CpG motif has a direct
antiproliferative and proapoptotic effect on A20.IIA
lymphoma cells, we sought to explore its effects in vivo
when injected intratumorally, by comparing the 3 types
of murine models of lymphoma: SCL, PCL and PIOL.
A20.IIA-GFP cells were implanted on the left and right
flank of the mice for the SCL model. Tumor size was
measured by a caliper 3 times a week. When the tumors
reached 5–7 mm in diameter, the left site was treated by
local injections of CpG- ODNs, while the right one was
used as an untreated control tumor. As described by
Houot & Levy in 2009 [14] mice did or did not receive
daily intratumoral injections of 100 μg/50μL CpG-ODNs
for 5 days. Tumor size was then measured daily until
sacrifice, one week after the last treatment injection. The
tumor burden of mice treated with CpG and control
ODNs was compared with a bioluminescence imaging
system that assessed total photon influx. The CpG-
ODNs inhibited tumor growth very soon after treatment
in this SCL model. On day 7 after treatment, the un-
treated tumor was more than 100 times brighter than
the CpG-treated one, and on day 20, 120 times brighter












f A20.IIA lymphoma cells in vitro. (A) Flow cytometric analysis of
), overlaid with isotype control (gray line). (B) CpG inhibits the
hours with various concentrations of CpG or control ODNs ranging
3H] thymidine was measured by a scintillation counter. *P < 0.05;
G induces apoptotic cell death of A20.IIA cell line. Cells were incubated
ne. The percentage of AnnV/PI positive cells was determined by flow
Figure 2 CpG-ODNs decrease the burden of subcutaneous and cerebral tumors but fail to induce PIOL regression. The 2-tumor-site SCL
model: (A) Representative bioluminescence images of SCL treated with control ODNs (upper panel) and CpG-ODNs (lower panel). The mice were
injected with 5x106 A20.IIA-GFP-luc2 cells. Treatment was injected in situ when the tumor reached 0.5 to 0.7 cm in diameter. (B) Flow cytometric
analysis of GFP+ CD19+ tumor cells, 7 days after the end of CpG-ODN administration in right tumors compared to left (untreated) tumors. PCL
lymphoma model: (C) Representative bioluminescence images of PCL mice treated with control ODNs (upper panel) and CpG-ODNs (both lower
panels), showing 2 different profiles of responsiveness to CpG motifs. The mice were injected with 5x104 A20.IIA-GFP-luc2 cells and treated one
week after tumor inoculation. (D) The percentage of CD19+ GFP+ tumor cells, as determined by flow cytometry, in the brain of mice treated with
CpG at 60 μg/2μL, in comparison with PBS 1X (Control)-injected mice (n = 5 per group). PIOL lymphoma model: (E) Representative
bioluminescence images of PIOL mice treated with control ODNs (upper panel) and CpG-ODNs (lower panel). The mice were injected with 104
A20.IIA-GFP-luc2 cells. CpG-ODN treatment was administered on day 0 intravitreously. (F) Flow cytometric analysis of the percentage of GFP+CD19+
tumor cells in PIOL-inoculated right eyes (n = 14 per group). A week after tumor injection, right eyes of mice were treated intravitreally by 20 μg/2 μL
of mice injected with CpG-ODNs or PBS 1X (Control). Results obtained from 2 independent experiments were pooled. Statistical test: Mann–Whitney;
NS: not significant.
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more in the treated than the untreated tumors
(Figure 2B).
We next addressed the question of whether CpG motifs
have the same antitumor effect in cerebral lymphomas. Im-
aging analysis showed two different profiles. Some mice did
not respond to in situ CpG-ODN treatment, and the lymph-
oma developed in the brain and even developed in lymphnodes at day 21; this timing was nonetheless later than in the
control group (Figure 2C – Example 1). Some mice did re-
spond to the treatment; the tumor grew from day 0 to day 7
after treatment, and then decreased until it was undetectable
(Figure 2C – Example 2). We also examined the percentage
of CD19+GFP+ cells in the group treated by CpG-ODNs,
compared it with the control group and observed a signifi-
cant decrease in the proportion of tumor cells (Figure 2D).
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ODNs on PIOL mice that had a tumor implanted in the
right eye only and were then treated with CpG-ODNs
(20 μg/2μL) or control ODNs (20 μg/μL). As shown in
Figure 2E, CpG-ODNs seem to have had no detectable
effects on the primary eye tumor. Nevertheless, they
appeared to prevent lymph node invasion at day 27
(Figure 2E). Flow cytometric analysis showed no signifi-
cant difference in tumor growth between CpG ODN-
treated and control (PBS 1X) treated eyes (Figure 2F).
These results suggest that the behavior of tumors in
the eye is different from that of systemic lymphomas,
but also from that of cerebral lymphoma, and thus, that
tumor cells responsiveness to CpG-DNA depend on the
tissue microenvironment.
Soluble molecules from the PIOL microenvironment
counteract the antiproliferative effect of CpG-ODNs on
malignant B-cells in a dose-dependent-manner
As described above, in vivo experiments showed that the
responsiveness of lymphoma B cells to CpG-ODN ad-
ministration was tissue-dependent. To confirm that theMedium
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ODN ctrl + PCL supernatant 
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Figure 3 PIOL supernatant counteracts in vitro antiproliferative effect
stimulated for 72 hours with various concentrations of CpG or control ODN
alone and with the presence of supernatant from (A) PBS 1X injected eyes
thymidine was measured by a scintillation counter. *P < 0.05; **P < 0.01. Thblockade of CpG-ODN antitumor effects was due to the
PIOL molecular microenvironment, we tested whether
supernatant from PIOL could counteract the inhibitory
effect of CpG-ODNs on the proliferation of A20.IIA cells
in vitro. A [3H] thymidine incorporation assay was
performed as described above, with the addition of super-
natant obtained from PBS-injected eyes (PIE) (as control),
or from the mouse model SCL, PCL, and PIOL. As shown
in Figure 3, the addition of PIE (Figure 3A) and SCL
(Figure 3B) supernatants did not modify the ability of
CpG-ODN treatment to inhibit tumor growth. PCL super-
natant (Figure 3C) increased proliferation, but CpG-
ODNs were still active at doses of 30 and 60 μg/mL. In
contrast, CpG-ODNs were unable to inhibit tumor cell
proliferation after incubation with PIOL supernatant
(Figure 3D) and to induce apoptosis (data not shown).
Moreover, their antiproliferative effect was recovered
upon dilution of the PIOL supernatant (Figure 4). These
data confirm our in vivo results and show that a soluble
factor, released in eye tumors but not in normal eyes, was
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of CpG-ODNs on A20.IIA malignant B cells. 104 cells were
s in concentrations ranging from 0.003 to 60 μg/mL or with medium
(PIE), (B) SCL, (C) PCL, or (D) PIOL. The incorporation of the [3H]



































Figure 4 Soluble molecule present in PIOL but not in normal ocular microenvironment is able to abrogate in vitro effect of CpG-ODNs
in a dose-dependent manner. 104 cells were stimulated for 72 hours with CpG or control ODNs at 30 μg/mL and in the presence of several
diluted doses of control supernatant (PIE) or PIOL supernatant (1X, 1/20, 1/35, 1/50, 1/75, 1/100, 1/200, 1/500). The incorporation of the [3H]
thymidine was measured by a scintillation counter. *P < 0.05; **P < 0.01.
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expression or the internalization of CpG-ODNs by tumor
cells
To investigate the possibility that the loss of the CpG-
ODNs antitumor action was associated with modulation
of TLR9 expression, we used flow cytometry to compare
TLR9 expression on A20.IIA cells after incubation with
supernatant from medium alone, PIOL or PIE. No differ-
ences were found between these conditions (Figure 5A).
Next we examined whether the PIOL molecular
microenvironment inhibited internalization of CpG
ODNs by tumor cells. FITC-labelled CpG 1826 ODNs
were added for 24 hours at a concentration of 3 μg/mL
to A20.IIA lymphoma cells in the presence of PIOL or
PIE supernatant. Flow cytometric analysis indicated that
FITC expression by tumor cells with PIOL supernatant
was similar to that incubated with PIE supernatant
(Figure 5B).These findings show that the addition of
PIOL supernatant does not modify CpG internalizationby lymphoma B-cells, even in vivo in our three model
(data not shown).
Discussion
The ultimate goal of cancer immunotherapy is to eradicate
tumors through vaccine strategies. Recent studies have
demonstrated that synthetic CpG-ODNs induce regression
of highly immunogenic tumors by engaging both the in-
nate and the adaptive immune systems. CpG-ODNs are
currently being tested in clinical trials for the treatment of
non-Hodgkin B-cell lymphoma, which expresses TLR9
[15]. However, only limited information is currently avail-
able about the sensitivity to CpG-ODNs of primary malig-
nant B-cells of different non-Hodgkin lymphoma entities.
Understanding their direct effect on malignant B-cells is
important as we consider how this potent class of agents
might be used in the immunotherapy of lymphoma.
Here, we found that A20.IIA malignant murine
cells, related to diffuse large B cells, express TLR9 and
Figure 5 The PIOL microenvironment did not modify TLR9 expression or internalization of CpG-ODNs by tumor cells. (A) 104 A20.IIA
cells were incubated with PIOL or PIE supernatant. 3 days later, cytometric analysis was performed of TLR9 expression by cells incubated with
PIOL supernatant, overlaid with isotype control and compared to TLR9 expression by cells incubated with PIE supernatant or medium alone.
(B) 104 A20.IIA cells were incubated for 24 hours with medium alone or with PIOL or PIE supernatant and in the presence or absence of FITC-
labeled CpG-ODNs at 3 μg/mL. FITC expression by A20.IIA tumor cells was analyzed by flow cytometry.
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reported previously, CpG-ODNs induce a dose-dependent
antiproliferative effect [16] and increase apoptotic cell
death [17]. This apoptosis has been described as caspase-
dependent and is accompanied by up-regulation of CD95/
Fas and its ligand [9]. Another group demonstrated that
TLR9 signaling by CpG-B ODNs leads to NF-kB-dependent
production of autocrine IL-10, which then activates JAK/
STAT pathway-dependent tyrosine phosphorylation of
STAT1 proteins and thereby engenders an apoptotic path-
way in human chronic lymphocytic leukemia B-cells [10].
Comparing primary B-cell lymphomas from patient sam-
ples, other authors have showed that cell responsiveness to
CpG-ODNs varies, with different degrees of activation and
apoptosis induction [9]. Several studies have reported that
CpG-ODNs induce activation of normal B-cells and block
apoptosis [7]. Although the molecular mechanisms of
these effects remain unclear, it has been suggested that
reactive oxygen species (ROS) and NFkB activation may
play a role [18].
An important question is whether the in vitro re-
sponses to CpG motifs that have been observed could
produce an in vivo antitumor effect on DLBCL lymph-
oma mouse models. We used 3 mouse models to begin
to answer this question: a primary systemic lymphoma
model (subcutaneous lymphoma) and 2 primary central
nervous system lymphoma subtypes (cerebral and ocular
lymphoma mouse models). The brain and eyes, consid-
ered to be immune sanctuaries, are relatively isolated
from the systemic immune system by anatomic and
physiologic barriers that maintain a local immune toler-
ance to protect neuronal cells from inflammation [19].
The use of these different models allowed us to compare
the responsiveness to CpG-ODNs of the same tumor
cells located in different immune microenvironments.Thus, we demonstrated that local administration of
CpG-ODNs into subcutaneous lymphoma decreased the
tumor burden. This effect is probably attributable to im-
mune cell activation of NK cells and DCs, which acti-
vates innate and adaptive immunity. In addition, the
CpG-ODNs inhibited proliferation and induced apop-
tosis of TLR9-positive tumor cell lines in vitro. Interest-
ingly, intratumor administration of CpG-ODNs induced
tumor regression of cerebral but not intraocular lymph-
oma. The similarity in origin and classification of PCL
and PIOL, which are related subsets sharing the particu-
larity of developing in different immune-privileged sites,
makes these results especially striking.
In addition, PIOL supernatant selectively abrogated the
inhibitory effects of CpG-ODNs in vitro, in contrast to
supernatant from nonmalignant eyes (PBS-injected eye)
or SCL. PCL supernatant, on the other hand, had an inter-
mediate inhibitory effect on the in vitro antiproliferative
action of CpG-ODNs. Together, these data suggest that
soluble factors are produced in the PIOL microenviron-
ment, to a lesser degree in the PCL microenvironment,
and not at all in subcutaneous microenvironment. These
factors can inhibit the effect of this TLR9 agonist on
lymphoma B-cells. This inhibition was not due to
downregulation of TLR9 expression or to a blockade of
CpG internalization by tumor cells. Further investigation
is needed to characterize TLR9-mediated signaling and
molecular mechanisms that might differ in the PIOL
microenvironment.
Conclusions
In conclusion, we showed here that, in addition to their
immune-enhancing effects, CpG-ODNs inhibit lymph-
oma B cell proliferation and induce apoptotic cell death
in vitro. They also reduced tumor growth in systemic
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the value of developing TLR9-targeted therapy with
CpG-B ODNs as a therapeutic agent for primary non-
Hodgkin B-cell lymphoma. Further investigation should
seek to identify and characterize the soluble factors from
the PIOL microenvironment that inhibit the effects of
CpG-ODNs and enable us to understand the potential
immunosuppressive effect on host immune response
that the ocular lymphoma microenvironment appears to
produce.
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